Reenav Pharma Private Limited - Due diligence report

A 360° intelligence report on Reenav Pharma Private Limited: trust score, financial health, credit view, compliance, directors, growth and d…

2018-04-18 Mumbai, Maharashtra Active Unlisted
Share
RP Reenav Pharma Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Reenav Pharma Private Limited — 360° Intelligence Report

Generated from MCA filings & public records
76/100
Trust Score
Low Risk

Reenav Pharma Private Limited is assessed as Low Risk with a Trust Score of 76/100. Reenav Pharma Private Limited is an active private limited indian non-government company incorporated in 2018, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a moderate compliance risk and moderate financial risk profile.

Report generated on 22 Jul 2026 from the latest processed filings. Reenav Pharma Private Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
76/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreModerate
70/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
90/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 90/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 0 satisfied (-).

Compliance Score: 70/100 Moderate
  • Company status is Active as per MCA.
  • Balance sheet slightly behind (Mar 2024).
  • 1 auditor resignation(s) filed - latest: B N Bhadricha & Co on 2019-01-19.
  • Delayed payments to MSME suppliers disclosed (16 disclosure(s)).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 95/100
NameDIN / PANDesignationAppointedTenureDIN status
ARVIND GOVIND VARIA 01234567 Director 01/04/2018 6 yrs Approved
RAJESHREE TRIKAMLAL GOR 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • No disqualified or deactivated DINs.
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Ascent Wellness And Pharma Solutions Private Limited
Subsidiaries
-
Group entities
-
Capital events
3 allotment(s) · 2 transfer(s)

Promoters hold a majority stake - exact percentages are part of the full report.

Group entityRelationship% held
Ascent Wellness And Pharma Solutions Private Limited Holding Company 74.00%

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Net margin improved to 2.1x.
Operating for 8 years.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
1 auditor resignation(s) on record - review the stated reasons.
MSME payment delays disclosed - latest outstanding 5.45 Lakh.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence73/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment79/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 12 events
29 Sep 2024
Last AGM held
Annual general meeting
31 Mar 2024
Latest balance sheet
Filed with ROC
24 Sep 2022
Director ceased
ANAND SUBRAMANIAN IYER
Director ceased
KALPANA SRINIVASAN
13 May 2022
Director ceased
JAY RAJESH MEHTA
31 Mar 2019
Share transfer (FY 2019)
24500.00000000 shares to Private Limited Solutions Ascent Health and Wellness
20 Feb 2019
Securities allotted
250000 Debentures - 25.00 Lakh raised
28 Dec 2018
Securities allotted
250000 Debentures - 25.00 Lakh raised
30 Nov 2018
Securities allotted
500000 Debentures - 50.00 Lakh raised
18 Apr 2018
Incorporated
Registered with Roc Mumbai
Director appointed
ARVIND GOVIND VARIA (Director)
Director appointed
RAJESHREE TRIKAMLAL GOR (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 24% over the last 4 financial year(s).
Net profit margin moved from 0.86 to 61%.
Net worth is positive.
2 active director(s) / partner(s); board looks stable and experienced.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a majority stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 3 security allotment(s) - amounts available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Brio Interactive Technologies Limited U72200DL2012PLC242110 Okhala, Delhi, India
Ambica Ispat Private Limited U27109TG1990PTC011816 Secunderabd, Andhra Pradesh, Telangana, India
Ksp Electro Engineering (India) Private Limited U31103WB2010PTC148671 Barasat - I, West Bengal, India
Dvijay Pharma U24230MH2003PTC140762 Nashik, Maharashtra, India
Super Specialities Pharma Warehousing & Logistics Private Limited U74900MH2012PTC233473 Mumbai, Maharashtra, India
Fenda Audio India Pvt Ltd U32309DL2005PTC143072 New Delhi, Delhi, India
Agarwal Steel Private Limited U27200WB2013PTC201977 Kolkata, West Bengal, India
Fronius International U29296PN2013FTC146072 Pune, Maharashtra, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Reenav Pharma Private Limited before audits and certifications: compliance score 70/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Reenav Pharma Private Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 90/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Reenav Pharma Private Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 76/100, distress signals and MSME payment-delay disclosures - know whether Reenav Pharma Private Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Reenav Pharma Private Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Reenav Pharma Private Limited an active company?

Reenav Pharma Private Limited has MCA status “Active” with a compliance score of 70/100 (Moderate).

Is Reenav Pharma Private Limited financially healthy?

Reenav Pharma Private Limited has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Reenav Pharma Private Limited?

Its overall Trust Score is 76/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Reenav Pharma Private Limited?

The ultimate holding entity is Ascent Wellness And Pharma Solutions Private Limited. 2 active director(s) are on record.

Does Reenav Pharma Private Limited have loans or charges against its assets?

No charges are registered against this company - an unencumbered balance sheet.

Is Reenav Pharma Private Limited up to date with its ROC filings?

Balance sheet slightly behind (Mar 2024). Overall compliance score: 70/100 (Moderate).

Is it risky to lend to Reenav Pharma Private Limited?

Its Credit Risk Score is 90/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.